Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Thank you for attending our Global Healthcare Conference. Today, I have the pleasure to host Joe Romanelli, President of Human Health International; and Peter Dannenbaum, Head of Investor Relations.

Pembrolizumab combined with chemoradiotherapy followed by pembrolizumab monotherapy significantly improved survival compared ...

Under a MOU signed between both the parties, Merck and Siemens have decided to expand their cooperation in Smartfacturing.

Merck and Daiichi Sankyo said a Phase 3 study evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who received prior EGFR tyrosine ...

Lack of a skilled talent pool, and slow logistics operations are among the major challenges that could discourage India’s ...

Nestled in verdant greenery, the innovation hub’s like-minded community, customisable workspaces and proximity to key ...

Pembrolizumab plus chemoradiotherapy improved survival in patients with previously untreated, high-risk locally advanced ...

We recently compiled a list of the 12 Best Blue Chip Stocks To Invest In According to Short Sellers. In this article, we are ...

We recently compiled a list of the 7 Best Stocks for Beginners with Little Money According to Analysts. In this article, we ...

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

Merck (NYSE:MRK) had declared $0.77/share quarterly dividend, Payable Oct. 7; for shareholders of record Sept. 16; ex-div ...